Market revenue in 2023 | USD 9,355.9 million |
Market revenue in 2030 | USD 15,109.9 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Insulin delivery devices |
Fastest growing segment | Insulin Delivery Devices |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Glucose Monitoring (BGM) Devices, Insulin Delivery Devices |
Key market players worldwide | Medtronic PLC, Abbott Laboratories, Roche Holding AG, Bayer AG, Johnson & Johnson, B. Braun, DexCom Inc, Insulet Corp, Ypsomed Holding AG, Sanofi SA, Novo Nordisk A/S ADR, Arkray |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetes devices market will help companies and investors design strategic landscapes.
Insulin delivery devices was the largest segment with a revenue share of 54.19% in 2023. Horizon Databook has segmented the Europe diabetes devices market based on blood glucose monitoring (bgm) devices, insulin delivery devices covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of diabetes and rising awareness about diabetes management & control are among the factors expected to contribute to the growth of this market over the forecast period. According to International Diabetes Federation report (2021), approximately 61 million people in Europe suffer from diabetes, which accounts for around one in 11 adults. Russian Federation, Germany.
The diabetes devices market in Europe is smaller than in North America, with some European countries exhibiting less than 5% market penetration. The difference in the market size of the two regions can be attributed to unfavorable reimbursement policies, market access issues of insulin pumps, and a lack of trained professionals in many European countries.
However, countries like Germany and France have over 15% penetration of insulin pumps compared to less than 5% in other EU countries. In 2021, Medtronic plc was the leading player in the diabetes devices market in the region. Other key players in the region include Hoffmann-La Roche AG, Ypsomed AG, and Insulet Corporation. Ypsomed AG is a key distributor of Insulin pumps in Europe.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe diabetes devices market , including forecasts for subscribers. This continent databook contains high-level insights into Europe diabetes devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account